Navigation Links
A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing
Date:11/25/2011

GOTHENBURG, Sweden, November 25, 2011 /PRNewswire/ --

Immunicum, which is developing cancer vaccines, has received approval from the Swedish Medical Products Agency to start its first clinical trial. The study will be conducted on kidney cancer patients at the University Hospital in Uppsala. At the same time, the company secures substantial financing to complete the clinical trial.

- It's a big and important step to test the vaccine on humans for the first time. Our animal studies have shown good results, so we feel safe to continue, says Jamal El-Mosleh, CEO of Immunicum.

Immunicum's patented cancer vaccine is based on over 20 years of research in the field of transplantation immunology and activates the body's own immune system to attack tumor cells. The Nobel Prize in Medicine was recently awarded the discoverer of dendritic cells and their role in immunological reactions, the same type of cells that Immunicum bases its vaccines on.

- However, our vaccines differ from other cancer vaccines. Traditionally, dendritic cell-based cancer vaccines are made from patients' own cells. This means that each vaccine must be specially made for each patient, which is expensive, complex and takes time. Moreover, it is physically stressful for the patient who is seriously ill, says Jamal El-Mosleh.

Immunicum's vaccine is based on using dendritic cells from healthy individuals and can thus be mass-produced, leading to significant commercial advantages.

The vaccine has been tested in animal studies to examine its therapeutic effect and tumors were reduced in both weight and volume. Toxicity studies have also been conducted to investigate possible side effects, especially with a focus on autoimmune diseases. The study showed no evidence of adverse side effects.

Through the green light from the Medical Products Agency, a clinical phase I/II trial will be initiated within the next few months on twelve patients with metastatic renal
'/>"/>

SOURCE Immunicum
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease
2. MaxCyte and Medinet to Present at the 10th International Symposium on Dendritic Cells in Kobe, Japan
3. Cell-based alternative to animal testing
4. Promega and Cellular Dynamics Partner to Validate Stem Cell-Based In Vitro Assays for Predicting Drug-Induced Cardiotoxicity
5. Dont Wait to Innovate: Future Pharmaceuticals Magazine Releases Its Issue on Innovation in IT, Cell-Based Therapy and Supply Chains
6. O2h and Hypoxium Announce an Agreement to Offer Hypoxiums Specialised In Vitro, Cell-Based Oncology Assays via O2hs Biology Affiliate Program
7. Stemgent, CellDesign Sign Co-Exclusive Marketing Agreement on Stem Cell-Based Adipocyte Research Products
8. MultiVu Video Feed: Geron Receives FDA Clearance to Begin Worlds First Human Clinical Trial of Embryonic Stem Cell-Based Therapy
9. MaxCyte Hosts Live Discussion with Industry Experts on the Challenges in Developing Cell-Based Screening Assays for Drug Discovery
10. The MaxCyte STX Scalable Transfection System to be Launched at the SBS Symposium on Cell-Based Assays
11. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)...  S&P Capital IQ (MHFI) announced today that ... on Abattis Bioceuticals Corp . ... specialty biotechnology company with capabilities through its wholly ... ingredients, bio-similar compounds, patented equipment and consulting services ... . The company seeks to capitalize on ...
(Date:3/25/2015)... Md. , March 25, 2015 Accelovance, ... named a finalist for "Best Contract Research Organization" at ... the World Vaccine Congress. This is ... a finalist for the award, winning for "Best Contract ... a "Highly Recommended" distinction in 2013. "We,re ...
(Date:3/25/2015)... UK (PRWEB) March 25, 2015 An ... natural ingredients in all forms of food nutrients, regulatory ... to a substantial rise in demand for natural astaxanthin ... have started to ramp up their capacities to satisfy ... both natural and synthetic source astaxanthin (used in nutraceuticals, ...
(Date:3/25/2015)... San Francisco, CA (PRWEB) March 25, 2015 ... Provide Support for Novel Mechanism of Action in ... March 25, 2015 – Cytokinetics, Incorporated (Nasdaq: CYTK) ... its fast skeletal muscle troponin activator tirasemtiv in ... from a Phase IIa “Evidence of Effect” or ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5Accelovance Nominated for 2015 Vaccine Industry Excellence (ViE) Awards 2Global Astaxanthin Market to Reach Value of USD 1.1 billion by 2020, Expects Industry Experts in New Report Available at MarketPublishers.com 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6
... Chemically Defined Structure Synthesized,in the Lab, Team Completes ... ROCKVILLE, Md., Jan. 24 A team of ... created the largest,man-made DNA structure by synthesizing and assembling ... JCVI-1.0. This work, published,online today in the journal Science ...
... Biomatrica, the biostability company,that offers innovative technologies for ... for preserving RNA at room,temperature, eliminating the need ... RNA has skyrocketed over the past years due ... gene expression studies. However, RNA samples are,difficult to ...
... More Patients, SUNNYVALE, Calif., Jan. 24 ... in the field of radiosurgery,announced today that the ... new and existing CyberKnife(R) customers. This new service ... of remote scientists,specializing in CyberKnife radiosurgery treatment planning, ...
Cached Biology Technology:Venter Institute Scientists Create First Synthetic Bacterial Genome 2Venter Institute Scientists Create First Synthetic Bacterial Genome 3Venter Institute Scientists Create First Synthetic Bacterial Genome 4Venter Institute Scientists Create First Synthetic Bacterial Genome 5Venter Institute Scientists Create First Synthetic Bacterial Genome 6Biomatrica's RNAstable(TM) Stabilizes RNA at Room Temperature 2Biomatrica's RNAstable(TM) Stabilizes RNA at Room Temperature 3Accuray Announces New Treatment Planning Service Offering 2Accuray Announces New Treatment Planning Service Offering 3Accuray Announces New Treatment Planning Service Offering 4
(Date:3/19/2015)... , March 19, 2015  NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces its ... a news clip that aired this week on ... . In a segment "The Next Great Thing", ... ,a new way to pay, and ,a really big breakthrough ...
(Date:3/16/2015)... 2015 Between 16 and ... groundbreaking innovations in biometric identification at the CeBIT ...      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ) ... well at the forefront: the company,s all new ... Germany . BiometricGate is the ...
(Date:3/11/2015)... and Markets ( http://www.researchandmarkets.com/research/3p32qm/access_control ) has announced ... Product, Application & By Geography - Global Forecast & ... This report predicts that the access control ... with an estimated CAGR of 10.6%. The ... as contact cards & readers, contactless cards & readers, ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2
... the genetic code for all sorts of biological molecules and ... code can similarly shape metallic structures. The team found ... tiny gold crystals that have many applications in medicine, ... of Chemistry at the U. of I., the team published ...
... operating in the abdomen. Instruments are inserted through a ... are visualized using an endoscope. This method is less ... of "minimally invasive intervention" could also be adopted by ... patients are buildings in need of upgrading to modern ...
... are transmitted to the inner ear via anterior extensions ... biologist Tanja Schulz-Mirbach explains how swim bladders may serve ... way. The anterior part of the swim bladder functions ... Up to now the effects of the different swim ...
Cached Biology News:Oh, my stars and hexagons! DNA code shapes gold nanoparticles 2Minimally invasive building renovation 2Minimally invasive building renovation 3Cichlid fish: How does the swim bladder affect hearing? 2
Determine relative degree of protein binding to phosphoinositides...
Anti-Protein Kinase-A (PKA) Regulatory subunit IIB; rabbit host...
... to PAX3 This protein is a ... of transcription factors. Members of the PAX ... and a paired-type homeodomain. These proteins play ... paired box gene 3 are associated with ...
Mouse polyclonal antibody to MCFD2 - multiple coagulation factor deficiency 2...
Biology Products: